New Insights into Continuous Glucose Monitoring (CGM)

by Colleen Fleiss on  October 3, 2018 at 8:02 AM Diabetes News
RSS Email Print This Page Comment bookmark
Font : A-A+

Significant reductions in mean glucose and other glycemic factors, with greater improvements were observed in patients taking metformin compared to insulin.
New Insights into Continuous Glucose Monitoring (CGM)
New Insights into Continuous Glucose Monitoring (CGM)

The design and results of this trial are published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT) website.

CGM was used to determine daily variations in glucose during the week before patients received dapagliflozin and during the last week of treatment. Dapagliflozin is a U.S. FDA-approved inhibitor of sodium-glucose cotransporter 2 (SGLT2) and by blocking SGLT2 it increases urinary glucose excretion and improves glucose control. CGM was able to show the effects of adding dapagliflozin to either metformin or insulin in terms of overall mean glucose concentration, fasting plasma glucose, postprandial glucose, time spent in the target glucose range, and glucose variability.

The article entitled "Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial," was coauthored by Robert Henry, MD, University of California San Diego School of Medicine and colleagues from UC San Diego School of Medicine, Integrated Medical Development (Princeton Junction, NJ), Medpace (Cincinnati, OH), and AstraZeneca (Fort Washington, PA).

"["As we move beyond A1c to measure glucose control, the use of CGM is becoming more important especially in insulin-requiring patients with diabetes. Time in range (TIR) and other metrics to measure glucose variability may closely relate with a patient's overall glucose control," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora). "Henry and colleagues emphasize the importance of adding an SGLT2 inhibitor on different metrics of glucose control as measured by CGM."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Diabetes - Foot Care Sugar: Time to Look beyond Its Sweetness Diabetic Ketoacidosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive